Market Access & Reimbursement

United States takes 1/3 of the global healthcare market, which is estimated to be 1.48 trillion U.S. dollars. However, the U.S. health policy landscape is rapidly evolving, with significant changes such as the Inflation React Act (IRA) empowering public payers to negotiate drug prices, and a major overhaul of Pharmacy Benefit Managers (PBM) and pharmacy operation models. To navigate these complexities, we collaborate with our partners to assist both large and small biopharmaceutical and medical device companies worldwide in planning their market access and reimbursement strategies. Our goal is to ensure that these companies are well-positioned to succeed in this dynamic and highly competitive market.

Our Insights on Data, Technology, and Healthcare
Understanding Health Technology Assessment (HTA): A Strategic Imperative for Innovators
Jul 15, 2025
If you're a scientist transitioning into the biotechnology sector or an entrepreneur developing a novel therapy for an unmet medical need, one term will...
Read more
Is Life Science Ready for AI?
Jan 01, 2025
A few days ago, Dr. Geoffrey Hinton, often referred to as the “Godfather of AI,” made a chilling statement: “There is a 10-20 percent probability that...
Read more
View all